IgG抗体(同型对照)

抗体药已成为生物医药发展的一个重要领域。抗体药开发过程中的同型对照(Isotype Control)抗体通常是指不会与已知或者潜在靶点有特异结合的一抗,但在类别和亚型上,跟开发过程中的针对靶点开发的一抗保持一致。
使用同型对照的目的是确定一抗的结合或效应是特异性的,排除非特异性的与Fc受体蛋白或与其他蛋白的相互作用;还可以作为竞争性结合Fc受体蛋白的抗体,与功能阻断抗体发挥同样的功能,这有利于对抗体药的药效进行有效合理的评估。非特异背景是一个需要控制的重要变量,设置对应的同型对照抗体来检测非特异性结合,从而减少假阳性结果的产生,可以更准确的评估药物开发过程中可能存在的影响因素。
ACROBiosystems百普赛斯可提供高性能的野生型与突变型抗体同型对照产品,助力加速您的研究进程。野生型Fc蛋白保留天然构象,为基础研究与对照实验提供可靠基准;突变型Fc基于临床抗体药物突变位点设计,精准匹配20+已上市抗体药的Fc工程化改造。这些经过严格验证的对照品具有高特异性和重复性,无内源性背景干扰,可确保流式细胞术(FACS)、酶联免疫吸附试验(ELISA)和表面等离子共振(SPR)等检测结果的可靠性。不论是基础研究还是新一代生物药开发,我们的同型对照都能为抗体发现、验证及治疗性抗体开发工作流程提供关键的标准化支持,助您研究更有把握。

产品优势

双Fc设计,灵活匹配需求

野生型Fc:保留天然构象,为突变体实验提供高可信度对照

突变型Fc:基于20+已上市抗体药物精准改造,直接匹配临床抗体特性

高稳定重复性

严格质控,确保批次间一致性

无内源背景干扰,数据更可靠

即用型多功能标签

直接兼容FACS、ELISA、SPR 等主流检测平台

产品列表

IgG1 Control
IgG2 Control
IgG3 Control
IgG4 Control

验证数据

高生物活性经ELISA验证

DNP-C11P1

Immobilized DNP-Albumin Conjugate, Bovine at 10 μg/mL (100 μL/well) can bind Human IgG1 (L234F,L235E,P331S) Kappa Isotype Control (mAb) (Cat. No. DNP-C11P1) with a linear range of 0.2-5 ng/mL (QC tested).

Protocol

DNP-M884

Immobilized Dinitrophenyl-BSA Conjugate (DNP-BSA) at 10 μg/mL (100 μL/well) can bind Human IgG2 (A330S, P331S) Kappa Isotype Control (mAb) (Cat. No. DNP-M884) with a linear range of 0.05-2 ng/mL (QC tested).

Protocol

DNP-M915

Immobilized DNP-Albumin Conjugate, Bovine at 10 μg/mL (100 μL/well) can bind Monoclonal Anti-DNP antibody, Human IgG3 Isotype Control (Cat. No. DNP-M915) with a linear range of 0.1-4 ng/mL (QC tested).

Protocol

DNP-M886

Immobilized Dinitrophenyl-BSA Conjugate (DNP-BSA) at 10 μg/mL (100 μL/well) can bind Human IgG4 (S228P, L235E) Kappa Isotype Control (mAb) (Cat. No. DNP-M886) with a linear range of 0.02-2 ng/mL (QC tested).

Protocol

经FACS验证可用作同型对照

DNP-BM1-F3

2e5 of Anti-CD19 CAR-293 cells were stained with 100 μL of 1 μg/mL of Biotinylated Mouse IgG1 Isotype Control (mAb) (Cat. No. DNP-BM1) and positive control respectively, washed and then followed by PE-SA and analyzed with FACS (Routinely tested).

Protocol

DNP-FM1-F3

2e5 of Anti-CD19 CAR-293 cells were stained with 100 μL of 1 μg/mL of FITC-Labeled Mouse IgG1 Isotype Control (mAb) (Cat. No. DNP-FM1) and positive control respectively, and FITC signal was used to evaluate the binding activity (Routinely tested).

Protocol

DNP-M1A1-F1

2e5 of anti-CD19 CAR-293 cells were stained with 100ul of 1:50 dilution of 2e5 of anti-CD19 CAR-293 cells were stained with 100ul of 1:50 dilution of Mouse IgG1 kappa Isotype Control (Cat. No. DNP-M1A1) and positive control antibody respectively, washed and then followed by PE anti-mouse IgG1 and analyzed with FACS (QC tested).

Protocol

DNP-BM190-F1

2e5 of anti-CD19 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) Biotinylated Mouse IgG1 kappa Isotype Control (Cat. No. DNP-BM190) and positive control antibody (Cat. No. FM3-BY54) respectively, washed and then followed by PE-SA and analyzed with FACS (QC tested).

Protocol

DNP-FM1A1-F1

2e5 of Anti-CD19 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of FITC-Labeled Mouse IgG1 Isotype Control (Cat. No. DNP-FM1A1) and positive control (Cat. No. FM3-FY45P1) respectively, and FITC signal was used to evaluate the binding activity (QC tested).

Protocol

DNP-PM1-F1

5e5 of Anti-CD19 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Monoclonal Mouse IgG1 Isotype Control (Cat. No. DNP-PM1) and positive control (Cat. No. FM3-HPY53) respectively, and PE signal was used to evaluate the binding activity (QC tested).

Protocol

  • 背景介绍
  • 产品优势
  • 产品列表
  • 验证数据